ERBB2 and breast cancer: At present, the management of breast cancer patients takes into consideration a combination of clinical and histopathological characteristics, together with the measurement of estrogen (ER) and progesterone (PR) hormone receptors and Her2/ERBB2 overexpression/amplification.